XML 49 R42.htm IDEA: XBRL DOCUMENT
v3.25.1

Fair Value Measurements of Financial Instruments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Fair Value Disclosures [Abstract] |
Schedule of Carrying Amounts and Fair Values of Financial Instruments | The carrying amounts and fair values of the Company’s financial instruments as of March 31, 2025, are presented below (in thousands):
|  | Fair Value Measurements |  |  |  |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Money market accounts* |  | $ | 2,755 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,755 |
Marketable securities – certificates of deposit |  |  | 2,313 |  |  |  | — |  |  |  | — |  |  |  | 2,313 |
Marketable securities – equity securities |  |  | 84 |  |  |  | — |  |  |  | — |  |  |  | 84 |
I Health call option |  |  | — |  |  |  | — |  |  |  | 3,867 |  |  |  | 3,867 |
Total assets |  | $ | 5,152 |  |  | $ | — |  |  | $ | 3,867 |  |  | $ | 9,019 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Interest rate collar |  | $ | — |  |  | $ | 21 |  |  | $ | — |  |  | $ | 21 |
AAMG contingent consideration |  |  | 2,075 |  |  |  | — |  |  |  | — |  |  |  | 2,075 |
VOMG contingent consideration |  |  | — |  |  |  | — |  |  |  | 15 |  |  |  | 15 |
Sun Labs remaining equity interest purchase |  |  | — |  |  |  | — |  |  |  | 7,352 |  |  |  | 7,352 |
ADSC contingent consideration |  |  | — |  |  |  | — |  |  |  | 4,309 |  |  |  | 4,309 |
CFC contingent consideration |  |  | — |  |  |  | — |  |  |  | 11,170 |  |  |  | 11,170 |
PCCCV contingent consideration |  |  | — |  |  |  | — |  |  |  | 1,450 |  |  |  | 1,450 |
CHS contingent consideration |  |  | — |  |  |  | — |  |  |  | 5,741 |  |  |  | 5,741 |
Total liabilities |  | $ | 2,075 |  |  | $ | 21 |  |  | $ | 30,037 |  |  | $ | 32,133 |
* Included in cash and cash equivalents The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2024, are presented below (in thousands):
|  | Fair Value Measurements |  |  |  |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Money market accounts* |  | $ | 3,673 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,673 |
Marketable securities – certificates of deposit |  |  | 2,289 |  |  |  | — |  |  |  | — |  |  |  | 2,289 |
Marketable securities – equity securities |  |  | 89 |  |  |  | — |  |  |  | — |  |  |  | 89 |
I Health call options |  |  | — |  |  |  | — |  |  |  | 3,778 |  |  |  | 3,778 |
Interest rate collar |  |  | — |  |  |  | 19 |  |  |  | — |  |  |  | 19 |
Total assets |  | $ | 6,051 |  |  | $ | 19 |  |  | $ | 3,778 |  |  | $ | 9,848 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
AAMG contingent consideration |  | $ | 2,110 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,110 |
VOMG contingent consideration |  |  | — |  |  |  | — |  |  |  | 15 |  |  |  | 15 |
Sun Labs remaining equity interest purchase |  |  | — |  |  |  | — |  |  |  | 7,352 |  |  |  | 7,352 |
ADSC contingent consideration |  |  | — |  |  |  | — |  |  |  | 4,285 |  |  |  | 4,285 |
CFC contingent consideration |  |  | — |  |  |  | — |  |  |  | 9,949 |  |  |  | 9,949 |
PCCCV contingent consideration |  |  | — |  |  |  | — |  |  |  | 1,351 |  |  |  | 1,351 |
CHS contingent consideration |  |  | — |  |  |  | — |  |  |  | 5,643 |  |  |  | 5,643 |
Total liabilities |  | $ | 2,110 |  |  | $ | — |  |  | $ | 28,595 |  |  | $ | 30,705 |
* Included in cash and cash equivalents
Schedule of Change in Fair Value of Level 3 Liabilities | The change in the fair value of Level 3 liabilities is recognized in unrealized loss on investments, other income, or general and administrative expenses in the accompanying condensed consolidated statements of income. As of March 31, 2025, the reconciliation of our Level 3 liabilities was as follows (in thousands):
|  | Amount |
Balance at January 1, 2025 |  | $ | 28,595 |
Change in fair value of existing Level 3 liabilities |  |  | 1,442 |
Balance at March 31, 2025 |  | $ | 30,037 |
Schedule of Change in Fair Value on Equity Securities Held | The change in fair value on equity securities held are as follows (in thousands) for the periods listed below and no securities had been sold in the respective periods:
|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Unrealized gains (losses) recognized on equity securities held at end of period |  | $ | 5 |  |  | $ | (116 | )

X
- Definition Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of realized and unrealized gain (loss) on investment in security. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_GainLossOnInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration